METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
Clinical trials for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) explained in plain language.
Never miss a new study
Get alerted when new METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) trials appear
Sign up with your email to follow new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo pill could shrink fatty liver and shed pounds
Disease control OngoingThis study tests an experimental drug called CS060380, taken with the weight-loss drug semaglutide, in adults with both fatty liver disease (MASH) and obesity. About 120 participants will be randomly assigned to get either CS060380 or a placebo for 36 weeks, then everyone gets CS…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
Phase: PHASE2 • Sponsor: Cascade Pharmaceuticals, Inc • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug aims to shrink fatty liver in early trial
Disease control OngoingThis early-stage study tests a drug called miricorilant in 8 people with MASH, a type of fatty liver disease linked to metabolism. The goal is to see if the drug can lower the amount of new fat the liver makes and reduce overall liver fat after 6 weeks. Participants must have cer…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
Phase: PHASE1 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New drug shows promise against fatty liver disease in Mid-Stage trial
Disease control OngoingThis study tests an experimental drug called miricorilant in 175 adults with nonalcoholic steatohepatitis (NASH), a serious fatty liver disease. Participants are randomly assigned to receive either the drug or a placebo, and researchers measure changes in liver fat using MRI scan…
Matched conditions: METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
Phase: PHASE2 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC